The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
Activate Your Account with an access code or Create a New Account
Andrew R. Rezvani, M.D.
Blood and marrow transplant specialist, Medical oncologist
Assistant Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Bio:
Dr. Rezvani is an Assistant Professor of Medicine in the Division of Blood & Marrow Transplantation at Stanford University. His focus includes clinical care of patients undergoing allogeneic and autologous hematopoietic cell transplantation, as well as clinical research aimed at improving outcomes and reducing complications of these transplants. He has conducted both retrospective and prospective clinical research in support of these aims. He also teaches and serves as a research mentor for fellows in the Division of Blood & Marrow Transplant at Stanford.
- 875 Blake Wilbur Drive
- Clinic E, 1st Floor
- Palo Alto , CA 94304
- Phone: 650-723-0822
Practice Areas
Professional Education
- Fellowship, Fred Hutchinson Cancer Research Center/University of Washington, Medical Oncology (2008)
- Residency, Duke University Medical Center, Internal Medicine (2004)
- M.D., Temple University, Medicine (2001)
- B.A., Stanford University, Slavic Languages and Literature (1997)
Honors & Awards
- Member, Alpha Omega Alpha medical honor society (2001)
Administrative Appointments
- Inpatient Medical Director, Blood & Marrow Transplant Unit, Stanford University (2017 - Present)
Publications
-
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., Maziarz, R. T., … Maloney, D. G. (2008). Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 26(2), 211–217. -
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., Sahebi, F., … Maloney, D. G. (2008). Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. BRITISH JOURNAL OF HAEMATOLOGY, 143(3), 395–403. -
Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies
Rezvani, A. R., & Storb, R. (2008). Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. EXPERT OPINION ON BIOLOGICAL THERAPY, 8(2), 161–179. -
Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation
Rezvani, A. R., & Storb, R. F. (2008). Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. JOURNAL OF AUTOIMMUNITY, 30(3), 172–179.
-
Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease
Flowers, M. E. D., Storer, B., Carpenter, P., Rezvoni, A. R., Vigorito, A. C., Campregher, P. V., … Martin, P. J. (2008). Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14(12), 1380–1384.
-
Allogeneic hematopoietic cell transplantation: the state of the art
Gyurkocza, B., Rezvani, A., & Storb, R. F. (2010). Allogeneic hematopoietic cell transplantation: the state of the art. EXPERT REVIEW OF HEMATOLOGY, 3(3), 285–299.
-
Rituximab resistance
Rezvani, A. R., & Maloney, D. G. (2011). Rituximab resistance. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 24(2), 203–216.
-
Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients
Yeh, R. F., Pawlikowski, M. A., Blough, D. K., McDonald, G. B., O'Donnell, P. V., Rezvani, A., … McCune, J. S. (2012). Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(2), 265–272.
-
Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
Rezvani, A. R., Storer, B. E., Storb, R. F., Mielcarek, M., Maloney, D. G., Sandmaier, B. M., … McDonald, G. B. (2011). Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1594–1601.
-
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
Scott, B. L., Gooley, T. A., Sorror, M. L., Rezvani, A. R., Linenberger, M. L., Grim, J., … Deeg, H. J. (2012). The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. BLOOD, 119(11), 2657–2664.
-
Prevention of graft-vs.-host disease
Rezvani, A. R., & Storb, R. F. (2012). Prevention of graft-vs.-host disease. EXPERT OPINION ON PHARMACOTHERAPY, 13(12), 1737–1750.
-
Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes
Rezvani, A. R., McCune, J. S., Storer, B. E., Batchelder, A., Kida, A., Deeg, H. J., & McDonald, G. B. (2013). Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(7), 1033–1039.
-
Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.
Sato, M., Storb, R., Loretz, C., Stone, D., Mielcarek, M., Sale, G. E., … Graves, S. S. (2013). Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target. Transplantation, 96(1), 34–41.
-
Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes
Rezvani, A. R., & Sandmaier, B. M. (2013). Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes. CURRENT OPINION IN HEMATOLOGY, 20(6), 509–514.
-
Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.
Rezvani, A. R., Storer, B. E., Guthrie, K. A., Schoch, H. G., Maloney, D. G., Sandmaier, B. M., & Storb, R. (2015). Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation , 21(1), 105–112.
-
Long-term outcomes of patients with persistent indolent b cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Cassaday, R. D., Storer, B. E., Sorror, M. L., Sandmaier, B. M., Guthrie, K. A., Maloney, D. G., … Gopal, A. K. (2015). Long-term outcomes of patients with persistent indolent b cell malignancies undergoing nonmyeloablative allogeneic transplantation. Biology of Blood and Marrow Transplantation , 21(2), 281–287.
-
Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Vaughn, J. E., Sorror, M. L., Storer, B. E., Chauncey, T. R., Pulsipher, M. A., Maziarz, R. T., … Maloney, D. G. (2015). Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer, 121(20), 3709–3716.
-
Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286–1292.
-
Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation
Andermann, T. M., Rezvani, A., & Bhatt, A. S. (2016). Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 11(1), 19–28.
-
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
Kanate, A. S., Mussetti, A., Kharfan-Dabaja, M. A., Ahn, K. W., DiGilio, A., Beitinjaneh, A., … Hamadani, M. (2016). Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. BLOOD, 127(7), 938–47.
-
A new standard for HIV-associated lymphoma.
Rezvani, A. R. (2016). A new standard for HIV-associated lymphoma. Blood, 128(8), 1026–1027.
-
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., … Miklos, D. B. (2016). Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Jun 2017
I wish all my doctors were like Dr. Rezvani. He always listens to me. Answers all my questions and concerns. he always takes his time.
SHC Patient, Jun 2017
Really like Dr. R.
SHC Patient, May 2017
Great!
SHC Patient, Mar 2017
Dr. Rezvani is wonderful. Always listens. Never makes me feel like we are keeping him from his work. Great doctor.
SHC Patient, Mar 2017
Very very confident in Dr. Rezvani -
SHC Patient, Feb 2017
Great doctor, very knowledgeable. Thank you very much.
SHC Patient, Oct 2016
Great doctor very happy with my experience!
SHC Patient, Sep 2016
Dr. Rezvani explained the transplant procedure in words all could understand and answered all questions. Very friendly and caring. Feel very lucky to have him.
SHC Patient, Aug 2016
My doctor all the time has been concerned about me, always listens to my symptoms or my concerns & always takes his time to explain my concerns or comments -
SHC Patient, Jul 2016
Dr. Rezvani did not rush through the visit and was very clear and patient answering my questions.
SHC Patient, Apr 2016
Very good experience, excellent representation (in detail) of illness!
SHC Patient, Mar 2016
Dr. Rezvani always gives me all the time & information I need - he's great!
SHC Patient, Mar 2016
I am very fortunate to have Dr. Rezvani as my BMT physician.
SHC Patient, Dec 2015
Dr. Rezvani is wonderful and caring doctor. Always clear on his explanations, very knowledgeable.
SHC Patient, Dec 2015
Dr. Rezvani took Dr. LaPorte's place. I scheduled an appt. to meet him personally. His agenda did not mesh with Ginna Laport's. He mentioned a transplant instead of Ginna's plan to keep me on maintenance meds. He should have consulted with her before she left. I do not want to return to Stanford.
SHC Patient, Sep 2015
Well prepared, good listener very bright.
SHC Patient, Aug 2015
Great experience.
SHC Patient, Jun 2015
The BMT Clinic is superlative.
SHC Patient, Jun 2015
Simply a good one.
SHC Patient, Mar 2015
Outstanding!
SHC Patient, Mar 2015
Very confident in Dr.Rezvani's knowledge, experience, and care. Always makes me feel taken care of.
SHC Patient, Mar 2015
Dr. Rezvani has been a pleasure to have as my treating physician.
SHC Patient, Jan 2015
I believe I am getting excellent care from Dr. Rezvani and Stanford in general.
SHC Patient, Jan 2015
Dr. Andrew Rezvani is an EXCELLENT listener and is SO KNOWLEDGEABLE about my case and the BMT process in general. He is an EXCELLENT doctor.
SHC Patient, Oct 2014
He is excellent. He really care for his patients.
SHC Patient, Oct 2014
Good.
SHC Patient, Jun 2017
I wish all my doctors were like Dr. Rezvani. He always listens to me. Answers all my questions and concerns. he always takes his time.
SHC Patient, Jun 2017
Really like Dr. R.
SHC Patient, May 2017
Great!
SHC Patient, Mar 2017
Dr. Rezvani is wonderful. Always listens. Never makes me feel like we are keeping him from his work. Great doctor.
SHC Patient, Mar 2017
Very very confident in Dr. Rezvani -
SHC Patient, Feb 2017
Great doctor, very knowledgeable. Thank you very much.
SHC Patient, Oct 2016
Great doctor very happy with my experience!
SHC Patient, Sep 2016
Dr. Rezvani explained the transplant procedure in words all could understand and answered all questions. Very friendly and caring. Feel very lucky to have him.
SHC Patient, Aug 2016
My doctor all the time has been concerned about me, always listens to my symptoms or my concerns & always takes his time to explain my concerns or comments -
SHC Patient, Jul 2016
Dr. Rezvani did not rush through the visit and was very clear and patient answering my questions.
SHC Patient, Apr 2016
Very good experience, excellent representation (in detail) of illness!
SHC Patient, Mar 2016
Dr. Rezvani always gives me all the time & information I need - he's great!
View All 26 Patient Comments »